Shots:

• The CE mark is granted under the new MDR European regulation- allowing the wearable therapeutic device to be marketed in selected EU countries- starting in 2021
• Nerivio has also received the US FDA’s approval for use in the acute treatment of migraine and is currently under review for chronic migraine. Nerivio is the first smartphone-controlled wearable device- connected with an app that keeps tracks of migraine episodes and provides analytics that a patient can share with their doctor- to help monitor and tailor treatment
• Nerivio is a wireless remote electrical neuromodulation device for the acute treatment of migraine with/out aura in patients ≥18yrs. who do not have chronic migraine. The device is self-applied to the upper-arm and should be used in the home environment at the onset of migraine headache or aura

­ Ref: Theranica | Image: Theranica